• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in the Study of 2-Methyl-5,6,7,8-tetrahydroquinazoline (CAS: 6299-01-0)

2-Methyl-5,6,7,8-tetrahydroquinazoline (CAS: 6299-01-0) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a scaffold for drug development, particularly in the context of central nervous system (CNS) disorders and infectious diseases. This research brief synthesizes the latest findings on this compound, highlighting its synthesis, biological activity, and potential clinical applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 2-Methyl-5,6,7,8-tetrahydroquinazoline derivatives exhibit potent inhibitory effects on monoamine oxidase B (MAO-B), an enzyme implicated in neurodegenerative diseases such as Parkinson's. The study utilized a combination of molecular docking and in vitro assays to identify key structural modifications that enhance selectivity and potency. These findings suggest that this compound could serve as a promising lead for developing novel neuroprotective agents.

In addition to its CNS applications, recent research has also investigated the antimicrobial properties of 2-Methyl-5,6,7,8-tetrahydroquinazoline. A 2024 preprint in BioRxiv reported that certain derivatives of this compound exhibit broad-spectrum activity against drug-resistant bacterial strains, including MRSA and Pseudomonas aeruginosa. The study employed a high-throughput screening approach to evaluate the compound's efficacy, revealing its potential as a scaffold for next-generation antibiotics.

From a synthetic chemistry perspective, advancements have been made in the efficient production of 2-Methyl-5,6,7,8-tetrahydroquinazoline. A recent Organic Letters publication (2024) described a novel catalytic method using palladium nanoparticles, which significantly improves yield and reduces reaction time compared to traditional approaches. This methodological innovation could facilitate large-scale production for preclinical and clinical studies.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of 2-Methyl-5,6,7,8-tetrahydroquinazoline derivatives. A 2023 review in Expert Opinion on Drug Discovery highlighted the need for further structure-activity relationship (SAR) studies to address issues such as metabolic stability and blood-brain barrier penetration. Future research directions may include computational modeling to predict optimal derivatives and in vivo studies to validate therapeutic efficacy.

In conclusion, 2-Methyl-5,6,7,8-tetrahydroquinazoline (CAS: 6299-01-0) represents a versatile scaffold with significant potential in drug discovery. Recent studies have expanded our understanding of its biological activities and synthetic accessibility, paving the way for its application in treating neurological and infectious diseases. Continued research in this area is expected to yield clinically relevant candidates in the coming years.

• 5632-33-7(5,6,7,8-Tetrahydroquinazoline)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)